Canaccord Genuity Reiterates Buy on Insulet Corp. (PODD)

By admin | 6 years ago

Insulet Corp. (NASDAQ: PODD)‘s stock had its “buy” rating restated by equities researchers at Canaccord Genuity in a report issued on Thursday.

Shares of Insulet Corp. traded up 0.11% during mid-day trading on Thursday, hitting $18.19. Insulet Corp. has a one year low of $14.00 and a one year high of $23.33. The company’s market cap is $867.9 million.

Insulet Corp. last announced its earnings results on Wednesday, May 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.03. The company’s revenue for the quarter was up 68.9% on a year-over-year basis. On average, analysts predict that Insulet Corp. will post $-0.21 earnings per share next quarter.

PODD has been the subject of a number of other recent research reports. Analysts at Avondale Partners initiated coverage on shares of Insulet Corp. in a research note to investors on Wednesday, April 18th. They set an “outperform” rating on the stock. Separately, analysts at Rodman & Renshaw upgraded shares of Insulet Corp. from a “market perform” rating to an “outperform” rating in a research note to investors on Wednesday, April 18th. Finally, analysts at Piper Jaffray (NYSE: PJC) initiated coverage on shares of Insulet Corp. in a research note to investors on Thursday, March 22nd. They set a “neutral” rating on the stock.

Insulet Corporation is a medical device company that develops, manufactures and markets an insulin infusion system for people with insulin-dependent diabetes.

About the author